NewsRelease

WhitepaperDescribes Stroma Liquid Biopsy™ Cancer Serum Biomarker Panel

Methods to monitorand potentially modulate the systemic response to cancer, offer newavenues for early detection, personalized medicine and therapeuticmodalities.

MONMOUTHJUNCTION, NJ,February27, 2019 -- Biotech Support Group announced today that it has published a whitepaper describing Stroma Liquid Biopsy™, a pan-cancer biomarker panel of dysregulation derived from blood.

Thetitle and download link is:

StromaLiquid Biopsy™ - Blood-based biomarkers to monitor stromalconditioning in cancer. Published February, 2019.

http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/StromaLiquidBiopsyWhitepaper022519.pdf

Thewhitepaper describes that tumors are more than simply a collection ofimmortalized cells asthe supporting microenvironments or stroma also contributes topathogenesis. Because of this, tumor characterization cannot befully characterized solely through the analyses of the tumor cellgenome – the current emphasis of liquid biopsy platforms. Sobecause tumors are more than just a mass of proliferating cells,cancer progression must take into consideration the influence ofthe multiple cell types and networks of proteins dynamicallyinteracting in active tumorigenesis. These are not simply passivebystanders.

Theunique significance of the Stroma Liquid Biopsy™ pan-cancerprofile is that dysregulation in blood was categorically intertwinedwith the most rudimentary needs of cancer: space, nutrients andimmune evasion. Moreover, the changes within the 13 biomarker panelall occur within an interdependent network of cascading proteolyticevents. Because proteolysis is irreversible, all species of life haveevolved molecular regulatory systems to control aberrancies. The mostdistinguished is a protease inhibitory family of regulators known asSERPINs. Although SERPINs circulate in a variety of functional on/offsub-forms, conventionally they are observed and reported in aggregate(i.e., ELISA). As a result, their influence on disease is missed. Usingcombined LC-MS peptide features and enzyme assay methods thatdirectly assess SERPIN function, rather than antigen presentation, wenow have evidence that there is an imbalance of functional SERPINsub-forms in the cancer population relative to that of a normalpopulation.

“Aswe now have patent pending methodsto monitor the influence of an overlooked protein family – theSERPINs, we now have s a fundamentally new way to think aboutmolecular dysregulation in blood from a cancer patient. As describedin our whitepaper, new insights will be extracted into theopportunistic mechanisms that drive cancer pathogenesis andmetastatic dissemination, and we advance how those might be unwoundtherapeutically to improve survival. Ournext goal is for rigorous investigations into progressive disease andresponse to therapies with partners and collaborators. This will beour first step towards the ultimate goal of validating biomarkersuseful in the clinic. We welcome inquiries to commercialize StromaLiquid Biopsy™ forthe many different applications it can serve including earlydetection, wellness and risk factor monitoring, oncology drugdevelopment and personalized therapy decisions,”said Dr. Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.

Forbusiness development inquires, contact:
MattKuruc 732-274-2866,[email protected]

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com